0571-86893171
工作日8:30-17:30
四正柏流式凋亡(Annexin V)试剂盒系列,SCI文献引用多,价优物美! 二维码
822
发表时间:2018-07-06 08:56作者:诺扬生物 4abio(四正柏)的前身-深圳晶美生物科技有限公司成立于1992年,是国内第一代生物科技公司。2000年以后,原BD PharMingen公司创始团队投资晶美公司。自2002年起,美方帮助晶美成立研发生产中心。 2009年初,四正柏在晶美公司研发生产中心的基础上成立,专注于单克隆抗体和细胞因子试剂的开发,生产和相关服务。经过6年的发展,四正柏目前可以提供经国际标准质控的400多种试剂盒和6000多种流式单抗,以极具竞争力的性价比销往全球市场(已经签约两家美国代理商和加拿大、英国、法国独家代理,并正在构建一个覆盖欧洲的销售网络)。 四正柏公司正以崭新的姿态参与国际竞争,成为科研试剂领域“中国制造”排头兵。 ![]() 产品列表
部分文献引用 ●Ning Ma, Ming‐Kang Zhang, Xiao‐Shuang Wang, etc. NIR Light‐Triggered Degradable MoTe2 Nanosheets for Combined Photothermal and Chemotherapy of Cancer. Advanced Function Materials First published: 22 June 2018. (IF: 21.95). 引用产品:Annexin V-FITC/PI Apoptosis Detection Kit ●Jiajia Shen, Pengyu Li, Xuejing Shao, etc. The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival. Cancer Research, January 2018. (IF: 9.122) 引用产品:Annexin V‐FITC/PI apoptosis detection kit作者单位:中国医学科学院和中国协和医科大学药物生物技术研究所生物化学系 文章链接:http://cancerres.aacrjournals.org/content/78/2/359.short ●Fangfei Niu, Yonghua Liu, Zongpan Jing, etc. Novel carbazole sulfonamide microtubule-destabilizing agents exert potent antitumor activity against esophageal squamous cell carcinoma. Cancer Letters ,April 28, 2018 Volume 420, Pages 60–71. (IF: 6.375) ●Zhoujiang Chen, Weiping Liu, Long Zhao, etc. Acid-Labile Degradation of Injectable Fiber Fragments to Release Bioreducible Micelles for Targeted Cancer Therapy. Biomacromolecules, 2018, 19 (4), pp 1100–1110.(IF: 5.246) ●Hanjie Yi, Xianglei Yan, Qiuyun Luo. A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma. Journal of Experimental & Clinical Cancer Research, 2018 37:97. (IF: 5.189) ●Xiaolei Ni, Xiaoming Cao, Yongquan Wu, etc. FSTL1 suppresses tumor cell proliferation, invasion and survival in non-small cell lung cancer. Oncology Reports, October 31, 2017. Pages:13-20.(IF: 2.662) ●XiaohuiYan, PengfeiLi, YihongZhan, etc. Dihydroartemisinin suppresses STAT3 signaling and Mcl-1 and Survivin expression to potentiate ABT-263-induced apoptosis in Non-small Cell Lung Cancer cells harboring EGFR or RAS mutation. Biochemical Pharmacology, Volume 150, April 2018, Pages 72-85. (IF: 4.581)
文章分类:
精品推荐
|